Pharmaceutical use of substituted amides

a technology of substituted amides and pharmaceuticals, applied in the direction of drug compositions, biocides, metabolic disorders, etc., can solve the problems of increased mortality of cardiovascular diseases, major global health problems, and metabolic syndrom

Inactive Publication Date: 2006-05-25
HIGH POINT PHARMA
View PDF2 Cites 122 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The metabolic syndrome is a major global health problem.
In type 2 diabetes, obesity and dyslipidemia are also highly prevalent and around 70% of people with type 2 diabetes additionally have hypertension once again leading to increased mortality of cardiovascular diseases.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical use of substituted amides
  • Pharmaceutical use of substituted amides
  • Pharmaceutical use of substituted amides

Examples

Experimental program
Comparison scheme
Effect test

example 10

1-[3-Acetyl-2-[5-(1,3,3-trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)-1H-indol-3-yl]-2,3-dihydro-imidazol-1-yl]-ethanone

[1359]

[1360] To a solution of imidazole (23 mg, 0.34 mmol) in acetic anhydride at 125° C. was added dropwise over 40 min a solution of (1H-Indol-5-yl)-(1,3,3-trimethyl-6-aza-bicyclo[3.2.1]oct-6-yl)-methanone (100 mg, 0.34 mmol) in acetic anhydride (13 mL). The resulting mixture was heated at 125° C. for 30 min then cooled and solvents evaporated in vacuo. The resulting residue was purified by preparative HPLC, dried in vacuo at 50° C. to afford 5.4 mg (4%) of the title compound as a solid.

[1361] MS-ESI m / z 449; 1H NMR (400 MHz, DMSO) δ 0.94 (d, 3H), 0.97 (d, 3H), 1.08-1.17 (m, 4H), 1.28-1.62 (m, 4H), 1.72-1.79 (m, 1H), 2.05-2.08 (m, 6H), 3.14-3.16 (m, 1H), 3.26-3.28 (m, 1H), 3.33-3.36 and 3.63-3.67 (2×m, 1H), 4.04-4.06 and 4.61-4.63 (2×m, 1H), 6.33-6.40 (m, 2H), 6.96-7.00 (m, 1H), 7.17-7.49 (m, 2H), 7.67-7.82 (m, 1H), 8.94 (s, 1H).

example 11

1-Ethyl-3-[5-(1,3,3-trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)-1H-indol-3-yl]-pyrrolidine-2,5-dione

[1362]

[1363] A solution of (1H-Indol-5-yl)-(1,3,3-trimethyl-6-aza-bicyclo[3.2.1]oct-6-yl)-methanone (100 mg, 0.34 mmol) and N-ethylmaleimide (127 mg, 1.01 mmol) in acetic acid (2 mL) was heated at 160° C. employing microwave irradiation for 1 hr. The solvents were evaporated in vacuo and the resulting residue purified by preparative HPLC, dried in vacuo at 50° C. to afford 25 mg (18%) of the title compound as a solid.

[1364] MS-ESI m / z 422; 1H NMR (400 MHz, CDCl3) δ 0.93-0.96 (m, 3H), 1.01-1.06 (m, 3H), 1.13-1.17 (m, 3H), 1.21-1.25 (m, 3H), 1.28-1.44 (m, 3H), 1.55-1.64 (m, 1H), 1.73-1.81 (m, 1H), 2.05-2.28 (m, 1H), 2.78-2.87 (m, 1H), 3.17-3.34 (m, 1H), 3.57-3.68 (m, 3H), 4.01-4.07 and 4.62-4.64 (2×m, 1H), 4.24-4.28 (m, 1H), 7.11-7.12 (m, 1H), 7.22-7.31 (m, 3H), 7.53-7.60 (m, 1H), 8.83 (s, 1H).

example 12

(3-Thiazol-2-yl-1H-indol-5-yl)-(1,3,3-trimethyl-6-aza-bicyclo[3.2.1]oct-6-yl)-methanone

[1365]

[1366] To a slurry of (1H-Indol-5-yl)-(1,3,3-trimethyl-6-aza-bicyclo[3.2.1]oct-6-yl)methanone (300 mg, 1.01 mmol) in benzene (8 mL) under an inert atmosphere of nitrogen was added methylmagnesium iodide (0.34 mL, 1.01 mmol), after stirring for 10 mins 2-bromothiazole was added where upon the mixture was heated at 90° C. for 16 hrs. Water (20 mL) was added and the organics were extracted with DCM (3×20 mL). The combined organic phases were dried (MgSO4), filtered and evaporated in vacuo. The residue was purified by preparative HPLC, dried in vacuo at 50° C. affording 48 mg (25%) of the title compound as a solid.

[1367] MS-ESI m / z 380; 1H NMR (300 MHz, CDCl3) δ 0.93-1.08 (m, 6H), 1.16-1.20 (m, 5H), 1.39-1.47 (m, 2H), 1.59-1.64 (m, 1H), 1.80-1.85 (m, 1H), 3.21-3.24 (m, 1H), 3.34-3.38 and 3.65-3.69 (2×m, 1H), 4.01-4.03 and 4.65-4.68 (2×m, 1H), 7.31-7.35 (m, 2H), 7.48-7.52 (m, 1H), 7.82 (d, 1H),...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The use of substituted amides for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11βHSD1 and may be useful in the treatment, prevention and / or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application is a continuation of International Application No. PCT / DK2004 / 000250, filed Apr. 6, 2004, which claims priority from Danish Patent Application Nos. PA 2003 00565, filed Apr. 11, 2003; PA 2003 00972, filed Jun. 27, 2003; PA 2003 00988, filed Jun. 30, 2003; PA 2003 00989, filed Jun. 30, 2003; PA 2003 00990, filed Jun. 30, 2003; PA 2003 00998, filed Jul. 2, 2003; PA 2003 01910, filed Dec. 22, 2003; and PA 2004 00009, filed Jan. 6, 2004; and U.S. Patent Application Nos. 60 / 467,800, filed May 2, 2003; 60 / 486,095, filed Jul. 10, 2003; 60 / 486,097, filed Jul. 10, 2003; 60 / 486,094, filed Jul. 10, 2003; 60 / 486,078, filed Jul. 10, 2003; 60 / 486,098, filed Jul. 10, 2003; and 60 / 537,099, filed Jan. 16, 2004.FIELD OF INVENTION [0002] The present invention relates to use of substituted amides and pharmaceutical compositions comprising the compounds for treating disorders where it is desirable to modulate the activity of 11-hydroxystero...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/496A61K31/495A61K31/453A61K31/165A61K31/445A61K31/16A61K31/415A61K45/06A61P3/04A61P3/10
CPCA61K31/16A61K31/415A61K45/06C07D209/02C07D401/06C07D401/12C07D403/12C07D487/08A61P3/00A61P3/04A61P3/10
Inventor ANDERSEN, HENRIKKAMPEN, GITA CAMILLACHRISTENSEN, INGEMOGENSEN, JOHNLARSEN, ANNETTEKILBURN, JOHN
Owner HIGH POINT PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap